181 related articles for article (PubMed ID: 35846145)
1. Prognosis Prediction Through an Integrated Analysis of Single-Cell and Bulk RNA-Sequencing Data in Triple-Negative Breast Cancer.
Wang X; Chen H
Front Genet; 2022; 13():928175. PubMed ID: 35846145
[No Abstract] [Full Text] [Related]
2. Identification of differentially expressed genes at the single-cell level and prognosis prediction through bulk RNA sequencing data in breast cancer.
Chen H; Tian T; Luo H; Jiang Y
Front Genet; 2022; 13():979829. PubMed ID: 36186437
[No Abstract] [Full Text] [Related]
3. Identification of a pyroptosis-related prognostic signature in breast cancer.
Chen H; Luo H; Wang J; Li J; Jiang Y
BMC Cancer; 2022 Apr; 22(1):429. PubMed ID: 35443644
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer.
Ruan Y; Tang Q; Qiao J; Wang J; Li H; Yue X; Sun Y; Wang P; Yang H; Liu Z
Front Oncol; 2023; 13():1171496. PubMed ID: 37274269
[TBL] [Abstract][Full Text] [Related]
6. Development of a CD8
Dai YW; Wang WM; Zhou X
Heliyon; 2023 Sep; 9(9):e19798. PubMed ID: 37810147
[TBL] [Abstract][Full Text] [Related]
7. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
8. High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer.
Liu X; Wu Y; Zhang Y; Bu D; Wu C; Lu S; Huang Z; Song Y; Zhao Y; Guo F; Ye P; Fu C; Shen L; Zhang J; Wang H; Duan X; Wu J
Front Oncol; 2021; 11():747300. PubMed ID: 34604090
[TBL] [Abstract][Full Text] [Related]
9. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
10. Correlation Between Immune Cell Infiltration and PD-L1 Expression and Immune-Related lncRNA Determination in Triple-Negative Breast Cancer.
Yang W; Qiu Z; Zhang J; Zhi X; Yang L; Qiu M; Zhao L; Wang T
Front Genet; 2022; 13():878658. PubMed ID: 35432487
[TBL] [Abstract][Full Text] [Related]
11. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract][Full Text] [Related]
12. Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics.
Wang N; Gu Y; Chi J; Liu X; Xiong Y; Zhong C; Wang F; Wang X; Li L
Front Genet; 2021; 12():721873. PubMed ID: 34408776
[No Abstract] [Full Text] [Related]
13. Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data.
Ju G; Zeng K; Lu L; Diao H; Wang H; Li X; Zhou T
Am J Cancer Res; 2023; 13(2):569-588. PubMed ID: 36895975
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a novel cytokine-related 8-gene signature for distinguishing and predicting the prognosis of triple-negative breast cancer.
Liu X; Zhang L; Chen L
Front Med (Lausanne); 2023; 10():1189361. PubMed ID: 37332770
[TBL] [Abstract][Full Text] [Related]
15. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract][Full Text] [Related]
16. The potent potential of MFAP2 in prognosis and immunotherapy of triple-negative breast cancer.
Huang J; Xu Y; Qi S; Zheng Q; Cui C; Liu L; Liu F
Discov Oncol; 2024 Jun; 15(1):202. PubMed ID: 38822944
[TBL] [Abstract][Full Text] [Related]
17. Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis.
Gao C; Li H; Liu C; Xu X; Zhuang J; Zhou C; Liu L; Feng F; Sun C
Front Immunol; 2021; 12():650491. PubMed ID: 33968045
[TBL] [Abstract][Full Text] [Related]
18. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma.
Jiang A; Wang J; Liu N; Zheng X; Li Y; Ma Y; Zheng H; Chen X; Fan C; Zhang R; Fu X; Yao Y
Front Genet; 2022; 13():833797. PubMed ID: 35154287
[No Abstract] [Full Text] [Related]
19. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
20. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
